Joint Formulary & PAD

Ethinylestradiol with norelgestromin - Contraception

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Patches
Associated Icons :
Restrictions / Comments :
Important

Not a cost-effective choice. Consider only if compliance issues/swallowing difficulties/malabsorption with oral CHC and LARC is unsuitable.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Ethinylestradiol with norelgestromin
Indication :
Contraception
Group Name :
Keywords :
combined hormonal contraceptive, CHC
Brand Names Include :
Evra
Important Information :

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Ethinylestradiol with norelgestromin is used to treat.

  • No records returned.

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.